Research I 04 February 2026
OECD cites EuroACT data in the new report on High Value Cancer Care
We are proud to share that the Organisation for Economic Co-operation and Development (OECD-OCDE) has published its 2026 report Delivering Hight Value Cancer Care, and EuroACT data has played a key role in shaping it. The report can be accessed here: https://lnkd.in/eRsupumz
EuroACT insights were used in two critical chapters of the OECD flagship report:
- Chapter 3 explores cross-country disparities in cancer clinical trials across the EU, drawing directly on EuroACT’s geographic analysis.
- Chapter 5 uses EuroACT evidence to assess the use of patient-reported outcomes (PROs) in oncology trials, highlighting gaps in how patient perspectives are captured and reported.
This recognition confirms EuroACT’s growing role as a patient-led evidence base driving real-world change in how cancer care is researched, understood, and made accessible.
We thank the OECD for acknowledging our contributions and look forward to continued collaboration, where EuroACT data is once again set to make an impact.
ABOUT THE PROJECT
EuroACT is a research project initiated by WECAN and the European Hematology Community. The project aims to understand the clinical trial landscape in the European region, based on data extracted from all relevant European clinical trial registers. Data from the past five years will unveil differences where clinical trials have been run in European countries and will describe how and which patient-reported outcomes (PROs) and quality-of-life (QoL) instruments have been used in clinical trials.
